This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum - Summary - MDSpire
Clinical Guidelines
Feature

This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum

Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma

  • April 21, 2026

  • 4 min

Share

Revolution Medicines' KRAS inhibitor daraxonrasib has shown promising results, with a Phase 3 trial indicating a significant increase in median overall survival for metastatic pancreatic cancer patients, reaching 13.2 months versus 6.7 months with standard chemotherapy. Notably, the treatment has been associated with skin toxicities, potentially impacting future treatment strategies. Meanwhile, GSK's antibody-drug conjugate Mo-Rez has demonstrated efficacy in chemotherapy-resistant gynecologic cancers, with plans for late-stage trials. Other industry movements include Gilead's acquisition of Tubulis for ADC capabilities and the introduction of interchangeable biosimilars for osteoporosis. The FDA is enhancing transparency with real-time CRL publications.

Original Source(s)

This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum

  • April 21, 2026

Related Content

Modeling the Genetics of Uveal Melanoma

Researchers have developed a genetically engineered mouse model that mirrors the genetic evolution of uveal melanoma

  • April 21, 2026

  • 3 min
This Week’s CGT News: New FDA Genome Editing Guidance 

Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T

  • April 20, 2026

  • 6 min
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...